Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors

NCT03678883 is registered in ClinicalTrials.gov with Actuate Therapeutics Inc. as lead sponsor.

NCT NCT03678883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03678883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
Lead sponsor
Actuate Therapeutics Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 4, 2019
Completion date
June 30, 2026
Enrollment
350 (estimated)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

acute t cell leukemia lymphoma, bone cancer, bone metastases, bone neoplasm, breast neoplasms, cancer, malignancies, malignancies multiple, malignant glioma, neoplasm metastasis, neoplasm of bone, neoplasm of lung, neoplasm, breast, neoplasms pancreatic, neoplasms,colorectal, pancreas cancer, pancreatic adenocarcinoma, pancreatic cancer, pancreatic neoplasms, refractory cancer, refractory neoplasm, refractory non-hodgkin lymphoma, renal cancer, resistant cancer, sarcoma